LC-K76

DIETARY_SUPPLEMENT2 trials

Sponsors

Shanghai Changzheng Hospital

Conditions

Prostate Cancer AdenocarcinomamCRPCmHNPCmHSPC

Early Phase 1

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Not yet recruitingNCT07389187

Shanghai Changzheng HospitalmCRPC

Start: 2026-02-01End: 2028-06-01Target: 10Updated: 2026-02-05

Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Not yet recruitingNCT07389174

Shanghai Changzheng HospitalmHNPC, mHSPC, Prostate Cancer Adenocarcinoma

Start: 2026-02-01End: 2027-06-01Target: 40Updated: 2026-02-05